Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287500 | 1.00 | MAPK1 (0.38) | MAPK1HPGDHDAC1HDAC6MAPT | |
| SCHEMBL14402458 | 0.87 | MAPK1 (0.39) | MAPK1HPGDMAPTCYP1A2NPSR1 | |
| SCHEMBL8119203 | 0.85 | MAPK1 (0.40) | MAPK1HPGDHDAC1HDAC6MAPT | |
| SCHEMBL4359331 | 0.85 | MAPK1 (0.40) | MAPK1HPGDHDAC1HDAC6MAPT | |
| SCHEMBL4359335 | 0.85 | MAPK1 (0.40) | MAPK1HPGDHDAC1HDAC6MAPT | |
| SCHEMBL6781077 | 0.83 | MAPT (0.42) | MAPK1HDAC1HDAC6MAPTKCNH2 | |
| SCHEMBL6781079 | 0.78 | MAPT (0.42) | MAPK1HDAC1HDAC6MAPTKCNH2 | |
| SCHEMBL23412392 | 0.78 | MAPK1 (0.47) | MAPK1HPGDMAPTCYP1A2NPSR1 | |
| SCHEMBL23412327 | 0.78 | MAPK1 (0.47) | MAPK1HPGDMAPTCYP1A2NPSR1 | |
| SCHEMBL23412328 | 0.78 | MAPK1 (0.47) | MAPK1HPGDMAPTCYP1A2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004282-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004282-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | MAPK1 4169/4885HPGD 3116/4885HDAC1 1530/4885 |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | MAPK1 4169/4885HPGD 3116/4885HDAC1 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.